Education
About Us
Working with TipRanks
Follow Us
Biovie Inc. (BIVI)
:BIVI
BIVI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.62 - $7.50
Previous CloseN/A
Volume1.62M
Average Volume (3M)248.32K
Market Cap
$19.13M
Enterprise Value$59.98M
Total Cash (Recent Filing)$23.15M
Total Debt (Recent Filing)$366.43K
Price to Earnings (P/E)―
Beta2.05
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.95
Shares Outstanding18,570,726
10 Day Avg. Volume199,948
30 Day Avg. Volume248,319
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)28.31
Price to Sales (P/S)0.00
P/FCF Ratio-24.11
Enterprise Value/Market Cap3.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-261.47
Enterprise Value/Ebitda-0.64
Forecast
1Y Price Target
$6.00Price Target Upside482.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
BioVie News
Options Prices
Currently, No data available
---
Ownership Overview
9.31% Insiders
3.98% Mutual Funds
0.39% Other Institutional Investors
83.37% Public Companies and Individual Investors
BIVI FAQ
What was Biovie Inc.’s price range in the past 12 months?
Biovie Inc. lowest stock price was $0.62 and its highest was $7.50 in the past 12 months.
What is Biovie Inc.’s market cap?
Biovie Inc.’s market cap is $19.13M.
When is Biovie Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Biovie Inc.’s earnings last quarter?
Biovie Inc. released its earnings results on Feb 14, 2024. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.275 by $0.055.
Is Biovie Inc. overvalued?
According to Wall Street analysts Biovie Inc.’s price is currently Undervalued.
Does Biovie Inc. pay dividends?
Biovie Inc. does not currently pay dividends.
What is Biovie Inc.’s EPS estimate?
Biovie Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biovie Inc. have?
Biovie Inc. has 18,570,726 shares outstanding.
What happened to Biovie Inc.’s price movement after its last earnings report?
Biovie Inc. reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.275. Following the earnings report the stock price went down -0.823%.
Which hedge fund is a major shareholder of Biovie Inc.?
Among the largest hedge funds holding Biovie Inc.’s share is Sheaff Brock Investment Advisors LLC. It holds Biovie Inc.’s shares valued at 0.
BioVie Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (482.52% Upside)
$6.00 (482.52% Upside)
Hedge Fund Trend
Decreased
By 5.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.80%
12-Months-Change
Fundamentals
Return on Equity
-93.23%
Trailing 12-Months
Asset Growth
-22.39%
Trailing 12-Months
Company Description
Biovie Inc.
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.